IBA renews interest in iSoft merger:
This article was originally published in Clinica
Executive Summary
Australian health information technology company IBA Health has submitted a revised cash offer of £166.3m ($330m), or 69p per share, for medical software supplier iSoft. IBA said it has agreed to buy around 56.6 million shares from iSoft shareholders, representing 24.3% of the company's issued capital. The revised offer trumps a 66p-per-share offer made on July 20 by fellow healthcare IT specialist CompuGROUP, based in Koblenz, German, which valued the deal at about £160m. IBA will receive a conditional investment of Aus$300m ($241m) from Allco Equity Partners on completion of the offer. Oxfordshire, UK-based iSoft claims to be one of the world's leading suppliers of advanced software applications for the healthcare sector, and was the main software supplier to the £12.4bn overhaul of the UK's National Health Service computer system.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.